Stratistics MRC에 따르면 세계의 급성 허혈성 뇌졸중 진단 및 치료 시장은 2025년 64억 달러를 차지하고 2032년에는 111억 달러에 이를 것으로 예상되며 예측 기간 중 CAGR은 8.1%를 나타낼 전망입니다.
급성 허혈성 뇌졸중(Acute Ischemic Stroke : 급성 허혈성 뇌졸중)은 동맥 폐색에 의해 유발되는 중대한 뇌혈관 이벤트이며, 뇌혈류의 저하와 잠재적인 신경세포 장애를 일으킵니다.
국제 당뇨병 연합의 최신 데이터에 따르면 2021년에는 전 세계에서 20-79세의 약 5억 3,700만명이 당뇨병을 앓았으며, 2030년에는 6억 4,300만명, 2045년에는 7억 8,300만명으로 증가할 것으로 예측되고 있습니다.
뇌졸중 발병률 상승
급성 허혈성 뇌졸중의 세계 유병률 증가는 시장의 중요한 촉진요인입니다. 요인은 뇌졸중의 위험을 더욱 악화시킵니다.
제한된 치료 프레임
급성 허혈성 뇌졸중 시장의 주요 억제요인 중 하나는 효과적인 치료를 위한 치료 기간이 제한되어 있다는 것입니다. 지연으로 인해 최적의 치료 기회를 놓치는 것도 적지 않습니다.
AI와 원격 의료의 통합
인공지능(AI)과 원격 의료의 통합은 급성 허혈성 뇌졸중 시장에 큰 기회를 가져옵니다. 이 지역에서도 실시간으로 치료 방침을 결정할 수 있습니다. 또한 AI를 활용한 예측 분석은 고위험자의 식별을 지원하고 예방 조치를 가능하게 합니다.
치료 관련 합병증의 위험
치료와 관련된 합병증의 가능성은 급성 허혈성 뇌졸중 시장에 위협을 초래합니다. 경계에서는 채용이 제한될 수 있습니다.치료 효과를 유지하면서 환자의 안전성을 확보하는 것은 여전히 중요한 과제입니다.
COVID-19 팬데믹은 급성 허혈성 뇌졸중 진단 및 치료 시장에 다양한 영향을 미쳤습니다. 기술의 채용이 가속화되었지만, 유방학은 원격 의료와 원격 모니터링의 중요성을 돋보이게 해, 유방학 후 뇌졸중 관리에서 더 큰 역할을 할 것으로 기대됩니다.
예측기간 동안 항혈소판약 분야가 최대가 될 전망
항혈소판 약물 부문은 혈전 형성을 예방하는 효과가 있기 때문에 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예상됩니다. 약제의 제제나 전달 방법의 진보에 의해 환자의 규정 준수와 치료 성적이 향상하고 있습니다. 또한, 뇌졸중 발병률 증가나 예방 의료의 중시, 계속적인 연구 개발에 의해 보다 효과적인 항혈소판 요법이 도입되어 시장에서의 지위가 확고해질 것으로 예상되는 것도 이 분야
예측 기간 동안 이미징 기술 분야의 CAGR이 가장 높아질 전망
예측 기간 동안 CT 스캔 및 MRI와 같은 이미징 기술의 혁신으로 진단 정확도와 속도가 향상됨에 따라 이미징 기술 분야가 가장 높은 성장률을 보일 것으로 예상됩니다. 아인프라에 대한 투자 증가는 이미징 기술의 채택을 촉진할 것으로 예상됩니다.
예측 기간 동안 북미가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 지역 시장 포지션을 더욱 강화하고 있습니다.뇌졸중 치료의 개선을 목적으로 한 정부의 대처가 성장에 기여하고 있습니다.
예측 기간 동안 의료 인프라의 급속한 개발과 의료비 증가로 아시아태평양이 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 조기 진단·치료의 중요성이 시장 수요를 밀어 올리고 있습니다.정부의 호의적인 정책이나 의료 액세스의 개선을 목표로 한 대처도, 성장에 기여하고 있습니다.
According to Stratistics MRC, the Global Acute Ischemic Stroke Diagnosis and Treatment Market is accounted for $6.4 billion in 2025 and is expected to reach $11.1 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Acute Ischemic Stroke (AIS) is a critical cerebrovascular event caused by an arterial occlusion, leading to reduced cerebral blood flow and potential neuronal damage. Emerging trends such as AI-driven stroke diagnostics and novel clot-retrieval devices are shaping market dynamics, fostering competition among pharmaceutical and medical device companies in the neurovascular sector.
According to the International Diabetes Federation's recent data, approximately 537 million people aged 20-79 years were living with diabetes worldwide in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045.
Rising stroke incidence
The increasing prevalence of acute ischemic stroke (AIS) globally is a significant driver for the market. Aging populations and the rising burden of cardiovascular diseases contribute to the growing incidence of stroke. Additionally, lifestyle factors such as sedentary habits, poor diet, and smoking further exacerbate the risk of stroke. Governments and healthcare organizations are also focusing on awareness campaigns to promote early detection and intervention. This surge in stroke cases is propelling the growth of the AIS diagnosis and treatment market.
Limited treatment window
One of the primary restraints in the AIS market is the narrow therapeutic window for effective treatment. The time-sensitive nature of stroke management limits the applicability of certain interventions, such as thrombolysis and thrombectomy. Delays in diagnosis or patient presentation to healthcare facilities often result in missed opportunities for optimal treatment. These challenges underscore the need for improved healthcare infrastructure and faster diagnostic protocols. The limited treatment window remains a critical barrier to market expansion.
AI and telemedicine integration
The integration of artificial intelligence (AI) and telemedicine presents a significant opportunity for the AIS market. AI-powered diagnostic tools can enhance the accuracy and speed of stroke detection, enabling timely intervention. Telemedicine facilitates remote consultations, allowing specialists to guide treatment decisions in real-time, even in underserved regions. Furthermore, AI-driven predictive analytics can aid in identifying high-risk individuals, enabling preventive measures. The growing investment in digital health solutions is expected to drive innovation and growth in this segment.
Risk of treatment-related complications
The potential for treatment-related complications poses a threat to the AIS market. Interventions such as thrombolytic therapy and mechanical thrombectomy carry risks of bleeding, infection, or vascular damage. Additionally, the high cost of advanced treatments and the associated risks may limit their adoption in resource-constrained settings. Ensuring patient safety while maintaining treatment efficacy remains a critical challenge. Addressing these concerns through improved protocols and safer therapeutic options is essential for market growth.
The COVID-19 pandemic has had a mixed impact on the AIS diagnosis and treatment market. On one hand, the focus on healthcare infrastructure and the need for rapid diagnostics during the pandemic accelerated the adoption of advanced technologies. However, the pandemic highlighted the importance of telemedicine and remote monitoring, which are expected to play a larger role in post-pandemic stroke management.
The antiplatelet drugs segment is expected to be the largest during the forecast period
The Antiplatelet Drugs segment is expected to account for the largest market share during the forecast period due to their efficacy in preventing clot formation. These drugs are critical in the management of acute ischemic strokes, reducing the risk of recurrence. The widespread adoption of antiplatelet drugs in clinical practice is driven by their proven benefits in stroke prevention. Advances in drug formulations and delivery methods are enhancing patient compliance and outcomes. Moreover, segment's growth is further supported by the increasing incidence of stroke and the emphasis on preventive care and continuous research and development are expected to introduce more effective antiplatelet therapies, solidifying their market position.
The imaging techniques segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Imaging Techniques segment is predicted to witness the highest growth rate due to Innovations in imaging technology, such as CT scans and MRI, are improving diagnostic precision and speed. The growing demand for advanced imaging solutions is driven by the need for early and accurate stroke detection. Increased investment in healthcare infrastructure, particularly in developing regions, is expected to boost the adoption of imaging techniques. Additionally, continuous advancements in imaging modalities are enhancing their capabilities, leading to better patient outcomes and collaborations between healthcare providers and technology firms are likely to accelerate the adoption of cutting-edge imaging solutions.
During the forecast period, the North America region is expected to hold the largest market share due to Increasing awareness about stroke symptoms and the importance of timely intervention is driving the demand for advanced diagnostic and treatment solutions. The presence of key market players and continuous investment in R&D further bolster the region's market position. Government initiatives aimed at improving stroke care are contributing to the growth. The rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes, is also expected to fuel the market.
Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR due to rapidly developing healthcare infrastructure and increasing healthcare expenditure. Countries like China, India, and Japan are at the forefront, with significant investments in healthcare technology and infrastructure. The growing awareness about stroke and the importance of early diagnosis and treatment is boosting market demand. Favorable government policies and initiatives aimed at improving healthcare accessibility are also contributing to the growth. The increasing prevalence of stroke and related risk factors, such as hypertension and diabetes, is expected to further drive market expansion.
Key players in the market
Some of the key players in Acute ischemic stroke diagnosis and treatment market include Abbott Laboratories, BIOTRONIK SE & Co KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Canon Medical Systems Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare Technologies Inc., Genentech, Inc. by Roche Group, Hitachi, Ltd., Integral Diagnostics (IDX) Group, Koninklijke Philips N.V., Mediso Kft., Medtronic PLC and Memorial Health.
In January 2025, Philips Healthcare planned to debut its Telestroke Connect Platform, a cloud-based telemedicine solution that links rural clinics with stroke specialists via augmented reality (AR). The platform will support live 3D imaging reviews and collaborative treatment planning, addressing gaps in access to specialized stroke care in underserved regions.
In March 2024, Siemens Healthineers launched the AI-Powered NeuroVision CT Suite, a next-generation imaging system designed to accelerate the detection of acute ischemic strokes. The suite integrates artificial intelligence to analyze brain scans in under 3 minutes, enabling rapid identification of blockages and guiding treatment decisions for thrombolysis or thrombectomy.
In February 2024, Medtronic introduced the Solitaire(TM) X Platinum+ Stent Retriever, an advanced thrombectomy device optimized for precision in removing blood clots. The device features enhanced flexibility and radial force, improving success rates in complex neurovascular anatomies while minimizing vessel trauma.